> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves CSL Behring’s Hizentra Expanded Use
- URL: https://www.fdaweb.com/fda-approves-csl-behrings-hizentra-expanded-use/
- Published: 2018-03-16T12:00:00.000Z
- Updated: 2026-09-14T23:53:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141001

FDA has approved CSL Behring’s Hizentra (immune globulin subcutaneous \[human\] 20% liquid) as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment. The approval was based on data from the Phase 3 [PATH](http://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2817%2930378-2/fulltext?ref=fdaweb.com) study, which demonstrated that the percentage of patients experiencing CIDP relapse or withdrawal for any other reason during treatment was significantly lower with Hizentra than with placebo. CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage. Hizentra is currently approved for treating certain immune deficiencies.